Post-operative Corticosteroid Treatment After Mitral Valve Surgery

Overview

The aim of the study is to intestigate whether three days intravenous corticosteroid management prevent atrial fibrillations in adults after mitral valve surgery. Prospective double-blinded randmized international multicenter study.

Full Title of Study: “Does Post-operative Corticosteroid Treatment Prevent New-onset Atrial Fibrillation After Mitral Valve Surgery?”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: Triple (Participant, Care Provider, Investigator)
  • Study Primary Completion Date: December 31, 2022

Detailed Description

Voluntary adult patients, who do not have persistent atrial fibrillation before mitral valve sugery will receive either intravenous corticosteroid or placebo on three postoperative days after mitral valve surgery. End points are atrial fibrillation onset or fullfilling the three days time limit. The study is double-blinded, randomized, prospective study and the aim is to recruite 240 patients. Patients are recruited from Oulu University Hospital, Finland, Kuopio University Hospital, Finland, Helsinki University Hospital, Finland, Turku University Hospital, Finland, Tampere Univerisity Hospital, Finland, Tartu University Hospital, Estonia, Tallinn Regionaalhaigla, Estonia and Liverpool Hospital, Sydney, Australia.

Interventions

  • Drug: Hydrocortisone
    • 100mg 1×3 hydrocortison intravenously for three days after mitral valve surgery or until atrial fibrillation onset
  • Drug: Placebos
    • 100mg 1×3 intravenous fysiologic saline for three days after mitral valve surgery or until atrial fibrillation onset

Arms, Groups and Cohorts

  • Experimental: Hydrocortisone
    • 100mg 1×3 hydrocortison intravenously for three days after mitral valve surgery or until atrial fibrillation onset
  • Placebo Comparator: Placebos
    • 100mg 1×3 intravenous fysiologic saline for three days after mitral valve surgery or until atrial fibrillation onset

Clinical Trial Outcome Measures

Primary Measures

  • atrial fibrillation
    • Time Frame: three days after mitral valve surgery
    • Atrial fibrillation onset in the timeframe of three postoperative days after mitral valve surgery.

Participating in This Clinical Trial

Inclusion Criteria

  • open mitral valve surgery – patients agrees to participate in the study – adult (minimum 18 years of age) Exclusion Criteria:

  • atrial fibrillation onset before first postoperative morning – prolonged intensive care unit stay (patient needs to stay in intensive care unit after first postoperative day) – patient is underaged, does not want to participate or can not make the decision by himself or herself because of ie memory disability – diabetes mellitus requiring insulin treatment and with recent hypo- or hyperglycemias which required hospital treatment – systemic mucous infections – known allergy or oversensitivity to hydrocortisone – Cushing syndrome – history of psychosis – history of ulcus or active ulcus – chronic atrial fibrillation or atrial flutter – corticosteroid or immunosuppressive treatment in use for any reason – active tuberculosis infection – severe renal impairment (serum creatinine 200 umol/l or over) – history of deep or superficial venous trombosis – Herpes simplex -ceratitis

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Kuopio University Hospital
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Jari Halonen, MD, PhD, Principal Investigator, general surgery attending, clinical teacher

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.